Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric study of recombinant von Willebrand factor with or without Advate for bleeding control, surgery, and pharmacokinetics in severe von Willebrand disease
2016-001477-33Phase 3Active
- Sponsor
- Baxalta
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa and recombinant human coagulation factor VIII in von Willebrand disease (VWD), sponsored by Baxalta. Primary endpoint: Hemostatic efficacy for nonsurgical bleeding episodes. Started Oct 2016; status: active.
02
Drugs
vonicog alfarecombinant human coagulation factor VIII
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2016-001477-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001477-33.